Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $1,602,300.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $106.82, for a total transaction of $1,602,300.00. Following the completion of the sale, the chief executive officer now owns 435,219 shares of the company’s stock, valued at $46,490,093.58. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Grant Pickering also recently made the following trade(s):

• On Monday, October 7th, Grant Pickering sold 7,098 shares of Vaxcyte stock. The shares were sold at an average price of $109.21, for a total transaction of $775,172.58.
• On Friday, August 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00.

Vaxcyte Price Performance

Shares of NASDAQ PCVX traded down $0.80 during mid-day trading on Monday, hitting $106.49. 549,530 shares of the company’s stock traded hands, compared to its average volume of 829,826. The company’s 50-day moving average is $109.48 and its two-hundred day moving average is $86.36. The company has a market capitalization of $11.89 billion, a P/E ratio of -22.75 and a beta of 1.01. Vaxcyte, Inc. has a 1 year low of $46.16 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter in the prior year, the company earned ($0.70) EPS. Equities analysts anticipate that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Bank of America lifted their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Mizuho lifted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Leerink Partners boosted their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. BTIG Research boosted their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC boosted their price objective on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $147.50.

Hedge Funds Weigh In On Vaxcyte

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Vaxcyte by 15.2% during the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after purchasing an additional 1,284,883 shares during the last quarter. RA Capital Management L.P. grew its stake in Vaxcyte by 4.0% in the 1st quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock worth $560,398,000 after acquiring an additional 312,500 shares in the last quarter. Janus Henderson Group PLC grew its stake in Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after acquiring an additional 692,492 shares in the last quarter. Capital Research Global Investors grew its stake in Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after acquiring an additional 700,414 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Vaxcyte by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock worth $216,966,000 after acquiring an additional 498,359 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.